ACE2 News and Research

RSS

All SARS-CoV-2 variants blocked by a simple peptide with nanomolar neutralizing efficacy

In a recent study published in the journal PNAS, researchers from Finland and the United States reported a novel heptad repeat 2 (HR2) peptide that inhibited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) without any chemical modifications.

21 Sep 2022

What is the efficacy of aerosol treatment for SARS-CoV-2 infection?

In a new study, researchers assessed the efficacy of the scFv76 antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lung damage.

21 Sep 2022

New antiviral mechanism of action for an FDA-approved thiopurine known as 6-thioguanine

Researchers described a novel antiviral mechanism of action for an FDA (food and drug administration)-approved thiopurine known as 6-thioguanine (6-TG).

21 Sep 2022

Prophylactic administration of SARS-CoV-2 specific immunoglobulin Y generated in chicken eggs displays protective effects in infected mice

A new study characterized and tested the antibody activity of SARS-CoV-2-specific immunoglobulin Y (IgY) derived from the eggs laid by chickens immunized with recombinant SARS-CoV-2 receptor binding domain (RBD) protein.

21 Sep 2022

Study reveals increased immunity evasion by Omicron BA.2.75.2

In a recent study posted to the bioRxiv* preprint server, researchers from ETH Zurich, Imperial College London, and Karolinska Institutet identified increased resistance to antibody-mediated neutralization by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineage BA.2.75.2.

21 Sep 2022

No adverse affect on sperm quality 6 to 14 months post BNT162b2 COVID vaccine

A study published in the journal Gamete Biology demonstrates that the mRNA-based coronavirus disease 2019 (COVID-19) vaccine developed by Pfizer/BioNTech is not detrimental to sperm health over a long period post-vaccination.

20 Sep 2022

Endogenous exosomes act as decoys for SARS-CoV-2

A recent study published in the journal PLoS Biology discussed exosomes as potential decoys for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

20 Sep 2022

Molecular engineered low-cost highly effective RBD-based COVID vaccine

In a recent study posted to the bioRxiv* preprint server, an international team of researchers developed a second-generation severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) antigen (RBD-J6) by molecular engineering with two additional amino acid (aa) substitutions (S383D and L518D mutations) in a hydrophobic cryptic RBD core epitope to enhance stability and expression against SARS-CoV-2 variants of concern (VOCs).

19 Sep 2022

SARS-CoV-2 N escape mutations do not affect rapid antigen testing

A new study maps the escape mutations found in various strains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could cause them to escape neutralization by antibodies or detection by rapid antigen tests that rely on antibody binding for a positive result.

16 Sep 2022

Development of improved monoclonal antibodies against SARS-CoV-2

In a new study, researchers explored strategies for the development of effective monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Sep 2022

Research shows a complex relationship between vaping and SARS-CoV-2 infection

In a recent study posted to the bioRxiv* pre-print server, researchers at the University of California, Riverside investigated the effects of electronic cigarette (EC) use as a risk factor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

14 Sep 2022

Defensosomes versus COVID-19

In a recent study published in the journal PLoS Biology, researchers investigated the role of angiotensin-converting enzyme 2 (ACE2)-containing defensive exosomes, or 'defensosomes' against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

14 Sep 2022

Intranasal administration of liposomes displaying SARS-CoV-2 antigen induces mucosal immunity

A new study suggested that an intranasal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine induced mucosal immune responses in mice.

14 Sep 2022

Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2

In a recent study published in the journal eBioMedicine, researchers in Denmark and Sweden administered a cationic liposome-adjuvanted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit vaccine as a subcutaneous (s.c.) prime-intranasal (i.n.) boost strategy to elicit mucosal immune responses among SARS-CoV-2-infected Syrian hamsters.

14 Sep 2022

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

In an article published in the journal Expert Opinion on Drug Safety, scientists have described the safety and efficacy profiles of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies in pregnant women with coronavirus disease 2019 (COVID-19).

13 Sep 2022

Saline nasal irrigation after COVID-19 diagnosis reduces hospitalization

Starting twice daily flushing of the mucus-lined nasal cavity with a mild saline solution soon after testing positive for COVID-19 can significantly reduce hospitalization and death, investigators report.

13 Sep 2022

Review of COVID-19 in children before and after SARS-CoV-2 Delta and Omicron variant emergence

Researchers provided a summary of SARS-CoV-2 infections among children pre- and post-SARS-CoV-2 Delta and Omicron variants of concern (VOCs) emergence.

12 Sep 2022

What is the impact of COVID-19 vaccination on erectile function?

A recent study reported that COVID-19 vaccination does not elevate the risk of erectile dysfunction.

12 Sep 2022

Interferon response induced by Omicron BA.1 and BA.5 prevents influenza A infection

In a recent study posted to the bioRxiv* preprint server, researchers in Germany and the United Kingdom investigated the interferon responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant and SARS-CoV-2 Omicron sub-variants BA.1 and BA.5, and their efficacy in protecting cells from influenza A virus super-infection.

12 Sep 2022

Discovery of antibodies that may eliminate the need for COVID vaccines

...

11 Sep 2022

ACE2 News and Research

All SARS-CoV-2 variants blocked by a simple peptide with nanomolar neutralizing efficacy

What is the efficacy of aerosol treatment for SARS-CoV-2 infection?

New antiviral mechanism of action for an FDA-approved thiopurine known as 6-thioguanine

Prophylactic administration of SARS-CoV-2 specific immunoglobulin Y generated in chicken eggs displays protective effects in infected mice

Study reveals increased immunity evasion by Omicron BA.2.75.2

No adverse affect on sperm quality 6 to 14 months post BNT162b2 COVID vaccine

Endogenous exosomes act as decoys for SARS-CoV-2

Molecular engineered low-cost highly effective RBD-based COVID vaccine

SARS-CoV-2 N escape mutations do not affect rapid antigen testing

Development of improved monoclonal antibodies against SARS-CoV-2

Research shows a complex relationship between vaping and SARS-CoV-2 infection

Defensosomes versus COVID-19

Intranasal administration of liposomes displaying SARS-CoV-2 antigen induces mucosal immunity

Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

Saline nasal irrigation after COVID-19 diagnosis reduces hospitalization

Review of COVID-19 in children before and after SARS-CoV-2 Delta and Omicron variant emergence

What is the impact of COVID-19 vaccination on erectile function?

Interferon response induced by Omicron BA.1 and BA.5 prevents influenza A infection

Discovery of antibodies that may eliminate the need for COVID vaccines

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News